Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on antibody-drug conjugate therapeutics, has granted stock options to seven new employees under its 2022 Inducement Plan. The grants total 382,518 shares, with 261,268 shares vesting over four years and 121,250 shares vesting on December 31, 2025.
The stock options have a ten-year term and an exercise price of $2.22 per share, matching Pyxis Oncology's closing stock price on September 30, 2025. These grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Pyxis Oncology (Nasdaq: PYXS), una società in fase clinica focalizzata sulle terapie con antibody-drug conjugate, ha concesso stock option a sette nuovi dipendenti nell'ambito del suo Piano di Induzione 2022. Le assegnazioni ammontano a 382.518 azioni, di cui 261.268 azioni vesting in quattro anni e 121.250 azioni vesting al 31 dicembre 2025.
Le stock option hanno una durata di dieci anni e un prezzo di esercizio di $2,22 per azione, pari al prezzo di chiusura delle azioni di Pyxis Oncology al 30 settembre 2025. Queste assegnazioni sono state effettuate come incentivi all'impiego in conformità con la Nasdaq Listing Rule 5635(c)(4).
Pyxis Oncology (Nasdaq: PYXS), una empresa en fase clínica centrada en terapéuticas de conjugados de anticuerpos, ha otorgado opciones sobre acciones a siete nuevos empleados bajo su Plan de Inducción 2022. Las concesiones suman 382.518 acciones, de las cuales 261.268 acciones se consolidarán durante cuatro años y 121.250 acciones vencerán el 31 de diciembre de 2025.
Las opciones tienen un plazo de diez años y un precio de ejercicio de $2,22 por acción, igualando el precio de cierre de las acciones de Pyxis Oncology al 30 de septiembre de 2025. Estas concesiones se realizaron como incentivos de empleo, en cumplimiento con la Nasdaq Listing Rule 5635(c)(4).
Pyxis Oncology (나스닥: PYXS), 항체-약물 결합 치료제를 중심으로 임상 단계에 있는 회사는 일곱 명의 신규 직원에게 2022년 유도 계획에 따른 주식 옵션을 부여했습니다. 총 382,518주로 구성되며, 261,268주는 4년간 취득하고 121,250주는 2025년 12월 31일에 취득합니다.
주식 옵션의 유효 기간은 10년이며 행사가격은 $2.22 달러 per 주당, 2025년 9월 30일 종가와 일치합니다. 이 부여는 고용 유인으로 이루어졌으며 Nasdaq Listing Rule 5635(c)(4)에 따라 이루어졌습니다.
Pyxis Oncology (Nasdaq: PYXS), une société en phase clinique spécialisée dans les thérapies à base d'anticorps-conjugués, a accordé des options d'achat d'actions à sept nouveaux employés dans le cadre de son Plan d'Induction 2022. Les attributions s'élèvent à 382 518 actions, dont 261 268 actions vesting sur quatre ans et 121 250 actions vesting le 31 décembre 2025.
Les options d'achat d'actions ont une durée de dix ans et un prix d'exercice de $2,22 par action, équivalant au cours de clôture des actions de Pyxis Oncology au 30 septembre 2025. Ces attributions ont été faites à titre d'incitations à l'emploi, conformément à la Nasdaq Listing Rule 5635(c)(4).
Pyxis Oncology (Nasdaq: PYXS), ein klinisches Unternehmen in der Phase, das sich auf Antibody-Drug-Conjugate-Therapeutika konzentriert, hat sieben neuen Mitarbeitern im Rahmen seines 2022 Inducement Plans Aktienoptionen gewährt. Die Zuteilungen belaufen sich auf 382.518 Aktien, davon 261.268 Aktien über vier Jahre vesten und 121.250 Aktien am 31. Dezember 2025 vesten.
Die Optionen haben eine Zehnjahreslaufzeit und einen Ausübungspreis von $2,22 pro Aktie, der dem Schlusskurs der Pyxis Oncology-Aktie am 30. September 2025 entspricht. Diese Zuteilungen erfolgten als Beschäftigungsanreize in Übereinstimmung mit der Nasdaq Listing Rule 5635(c)(4).
Pyxis Oncology (بورصة ناسداك: PYXS)، شركة في طور klinّي تتركّز على علاجات مترافقة antibody-drug، منحت خيارات أسهم لـسبعة موظفين جدد بموجب خطة الاستقدام لعام 2022. إجمالي المنح 382,518 سهماً، مع 261,268 سهماً ستُكتسب على مدى أربع سنوات و121,250 سهماً ستكتسب في 31 ديسمبر 2025.
تملك خيارات الأسهم فترة عشر سنوات وممارسة بسعر $2.22 دولار للسهم، بما يتماشى مع سعر إغلاق سهم Pyxis Oncology في 30 سبتمبر 2025. تم منح هذه الجوائز كحوافز وظيفية امتثالاً لقاعدة Nasdaq Listing Rule 5635(c)(4).
Pyxis Oncology (纳斯达克：PYXS)，专注于抗体药物偶联物治疗的临床阶段公司，已在其2022年引导计划下为七名新员工授予股票期权。此次授予总计382,518股，其中261,268股将在四年内归属，121,250股将于2025年12月31日归属。
这些股票期权的期限为十年，行权价为$2.22美元/股，等同于2025年9月30日的收盘价。此次授予是出于就业诱导，符合纳斯达克上市规则5635(c)(4)。
- Attraction of new talent with equity-based compensation
- Structured vesting schedule promotes employee retention
- Potential dilution of existing shareholders from new stock options
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 382,518 shares of Pyxis Oncology’s common stock to seven newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan (the ‘Plan’) with a grant date of September 30, 2025, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).
An aggregate of 261,268 stock options vest over four years, with
Pyxis Oncology is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors.
To learn more, visit www.pyxisoncology.com or follow us on X (formerly known as Twitter) and LinkedIn.
Pyxis Oncology Contact
Jitu Wadhane
Principal Financial and Accounting Officer
IR@pyxisoncology.com
FAQ
How many stock options did Pyxis Oncology (PYXS) grant to new employees in September 2025?
What is the exercise price for PYXS stock options granted on September 30, 2025?
What is the vesting schedule for Pyxis Oncology's September 2025 stock option grants?
Why did Pyxis Oncology (PYXS) issue these stock options?
